Wolfe Research reiterated an Outperform rating and $150 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about ...
RBC Capital reiterated an Outperform rating and $247 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about its ...
West Pharmaceutical’s earnings results led to a 38% drop. Find out why WST stock could be worth watching for future rebounds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback